Investigating PSMA-PET/CT to resolve prostate MRI PIRADS4-5 and negative biopsy discordance

[1]  N. Lawrentschuk,et al.  PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer , 2022, BMJ Open.

[2]  D. Murphy,et al.  High PSMA PET SUVmax in PI-RADS 4 or 5 men confers a high probability of significant prostate cancer. , 2022, BJU international.

[3]  D. Murphy,et al.  The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis , 2022, The Journal of Nuclear Medicine.

[4]  D. Margel,et al.  Diagnostic Performance of 68Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer. , 2021, Radiology.

[5]  H. Woo,et al.  The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. , 2021, European urology.

[6]  M. Ng,et al.  Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Steve Y. Cho,et al.  Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study , 2021, Clinical Cancer Research.

[8]  M. Ng,et al.  [18F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Daniel M. Costello,et al.  Funding of prostate magnetic resonance imaging leads to fewer biopsies and potential savings to health systems in the management of prostate cancer , 2020, BJU international.

[10]  N. Lawrentschuk,et al.  Detection and localisation of primary prostate cancer using 68gallium prostate‐specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology , 2020, BJU international.

[11]  N. Lawrentschuk,et al.  Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. , 2020, European urology.

[12]  N. Lawrentschuk,et al.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study , 2020, The Lancet.

[13]  F. Montorsi,et al.  Interreader variability in prostate MRI reporting using Prostate Imaging Reporting and Data System version 2.1 , 2020, European Radiology.

[14]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[15]  H. Woo,et al.  Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross‐sectional study of the additive diagnostic value of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for me , 2020, BJU international.

[16]  D. Margolis,et al.  Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. , 2019, European urology.

[17]  T. Sutherland,et al.  Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study , 2019, BJU international.

[18]  Nathan Lay,et al.  Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI. , 2019, AJR. American journal of roentgenology.

[19]  F. Maclean,et al.  68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology , 2018, Prostate Cancer and Prostatic Diseases.

[20]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[21]  Stig Müller,et al.  Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA , 2018, World Journal of Urology.

[22]  H. G. van der Poel,et al.  What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. , 2017, European urology.

[23]  Thomaz R. Mostardeiro,et al.  Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate. , 2017, AJR. American journal of roentgenology.

[24]  L. Hooft,et al.  Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique? , 2017, European urology.

[25]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .

[26]  Hedvig Hricak,et al.  How Sure Are You, Doctor? A Standardized Lexicon to Describe the Radiologist's Level of Certainty. , 2016, AJR. American journal of roentgenology.

[27]  Tristan Barrett,et al.  Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI‐transrectal ultrasonography (TRUS) fusion‐guided transperineal prostate biopsies as a validation tool , 2016, BJU international.

[28]  A. Haese*,et al.  PSMA Expression is Highly Homogenous in Primary Prostate Cancer , 2015, Applied immunohistochemistry & molecular morphology : AIMM.

[29]  N. Lawrentschuk,et al.  Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens. , 2019, BJU international.